{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:56:57Z","timestamp":1775534217155,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":1306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017030313830"],"award-info":[{"award-number":["2017030313830"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbes and Infection"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.micinf.2020.05.012","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T13:47:13Z","timestamp":1589982433000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study"],"prefix":"10.1016","volume":"22","author":[{"given":"Ping","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-687X","authenticated-orcid":false,"given":"Li","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.micinf.2020.05.012_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A\u00a0novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.micinf.2020.05.012_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.micinf.2020.05.012_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","article-title":"Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the kingdom of Saudi arabia","volume":"16","author":"Al Ghamdi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.micinf.2020.05.012_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/jac\/dkv085","article-title":"IFN-\u03b12a or IFN-\u03b21a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study","volume":"70","author":"Shalhoub","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.micinf.2020.05.012_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/vir.0.061911-0","article-title":"Interferon-\u03b2 and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays","volume":"95","author":"Hart","year":"2014","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.micinf.2020.05.012_bib6","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in\u00a0vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.micinf.2020.05.012_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biopha.2017.04.091","article-title":"Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in\u00a0vitro and in\u00a0vivo (mice and ferret)","volume":"91","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.micinf.2020.05.012_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.micinf.2020.05.012_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.intimp.2018.09.043","article-title":"The antiviral activity of arbidol hydrochloride against herpes simplex virus type II (HSV-2) in a mouse model of vaginitis","volume":"68","author":"Du","year":"2019","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.micinf.2020.05.012_bib10","first-page":"E001","article-title":"[Interpretation of \"guidelines for the Diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the national health commission (trial version 5)\"]","volume":"100","author":"Lin","year":"2020","journal-title":"Zhonghua Yixue Zazhi"},{"key":"10.1016\/j.micinf.2020.05.012_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1148\/radiol.2020200230","article-title":"CT imaging features of 2019 novel coronavirus (2019-nCoV)","volume":"295","author":"Chung","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.micinf.2020.05.012_bib12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.micinf.2020.05.012_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.micinf.2020.05.012_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.micinf.2020.05.012_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.micinf.2020.05.012_bib16","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.micinf.2020.05.012_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/fvl.11.33","article-title":"Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy","volume":"6","author":"Barnard","year":"2011","journal-title":"Future Virol"},{"key":"10.1016\/j.micinf.2020.05.012_bib18","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.micinf.2020.05.012_bib19","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J\u00a0Infect"}],"container-title":["Microbes and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286457920300903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286457920300903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T14:37:06Z","timestamp":1761143826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1286457920300903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":19,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1286457920300903"],"URL":"https:\/\/doi.org\/10.1016\/j.micinf.2020.05.012","relation":{},"ISSN":["1286-4579"],"issn-type":[{"value":"1286-4579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Microbes and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micinf.2020.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Institut Pasteur.","name":"copyright","label":"Copyright"}]}}